 developing next-generation immunomodularity drugs and their combinations in multiple myeloma. Physicians are faced with complex opportunities and challenges when combining and sequencing therapies to mitigate risk and maximize long-term patient benefit. In this trending 2021 research perspective published by Uncle Target, the authors wrote about these opportunities and challenges when treating either new or relapsed multiple myeloma patients. Read this research perspective and more peer-reviewed oncology-focused research published by Uncle Target at alcatarget.com